Asitapreg M tablets from Asitanila Remedies: A sophisticated pharmaceutical formulation integrating Pregabalin in a sustained-release matrix with the neurotrophic agent Methylcobalamin, designed for the sustained alleviation of neuropathic pain and the support of peripheral nerve health. Asitapreg M presents a rationally designed combination of two pharmacologically distinct entities: Pregabalin IP 75 mg (Extended-Release Matrix): Pregabalin, a structural analogue of gamma-aminobutyric acid (GABA), exerts its primary analgesic effect by binding to the α2​δ subunit of voltage-gated calcium channels (VGCCs) within the central nervous system. This interaction leads to a reduction in calcium influx at nerve terminals, consequently inhibiting the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, thereby attenuating neuronal hyperexcitability associated with neuropathic pain. The extended-release (ER) formulation of Pregabalin in Asitapreg M employs a specialized hydrophilic matrix system engineered to provide a controlled and prolonged release of the active pharmaceutical ingredient (API) into the gastrointestinal tract. Methylcobalamin IP 1500 mcg: A biologically active coenzyme form of Vitamin B12, Methylcobalamin participates in crucial biochemical pathways involved in nerve function and regeneration. It acts as a cofactor in methionine synthase, an enzyme essential for the synthesis of S-adenosylmethionine, a methyl donor involved in myelin sheath formation and nerve fiber maintenance. Methylcobalamin supplementation is indicated in Vitamin B12 deficiency-related neuropathies and may exert neurotrophic effects in other peripheral neuropathic conditions. Asitapreg M- Engineered for Sustained Efficacy and Enhanced Neuroprotection The distinct advantages of Asitapreg M stem from its synergistic composition and the advanced drug delivery system Dual-Target Pharmacological Action: The combination addresses both the symptomatic relief of neuropathic pain via Pregabalin\'s modulation of neuronal excitability and the potential for neurotrophic support through Methylcobalamin\'s involvement in nerve metabolism. Optimized Pharmacokinetic Profile via Sustained Release: The sustained -release (SR) formulation of Pregabalin (75 mg) in Asitapreg M is meticulously designed to achieve: Prolonged Drug Release Kinetics: The hydrophilic matrix system facilitates a gradual and controlled dissolution of Pregabalin over an extended period, resulting in a more sustained plasma concentration-time profile compared to immediate-release formulations. Minimized Peak-to-Trough Fluctuations: This controlled release helps to reduce the sharp peaks in plasma drug concentration, potentially mitigating the incidence of concentration-dependent adverse events (e.g., somnolence, dizziness) and maintaining therapeutic drug levels for a more consistent analgesic effect. Enhanced Bioavailability Profile (Targeted): The ER formulation aims to optimize the absorption of Pregabalin over a prolonged period, contributing to sustained therapeutic efficacy. Neurotrophic Support Adjunct: The inclusion of a pharmacologically relevant dose of Methylcobalamin (1500 mcg) provides adjunctive support for nerve health, potentially contributing to nerve regeneration and functional recovery in certain neuropathic conditions. Quality Manufacturing Standards: Asitapreg M is produced by Asitanila Remedies under strict adherence to current Good Manufacturing Practices (cGMP), ensuring consistent product quality, purity, and efficacy.